D Medical Industries reports that its subsidiary Spring-Set Health Solutions Ltd. has successfully completed a study of usability and security of its spring report of the Universal Infusion for delivery of insulin and other drugs from a insulin pump.
The study included 48 patients in a medical center in New York. The study examined the interfaces between users, systems and operating environments, the user ends successfully in carrying out each task. D Medical has concluded: “Most users had higher scores for satisfaction and the product has been classified as safe for use by the target population.”
D Medical Hezkiah Tsoory operations manager, said: “We conducted this study in preparation, in anticipation of the Food and Drug order lexapro generic Administration (FDA) 510 (k) for our spring games infusion universal. This major achievement was reached earlier this week. But as we make final preparations for the deployment of the United States, we are convinced that the obvious benefits of this product is going to win the hearts and minds of the American pump users. ”
Share price closed at $ 4.79 D Medical yesterday on Nasdaq, after rising 60% on Monday, giving it a market capitalization of $ 37 million. The share price fell 5.6% in the afternoon on the TASE today to NIS 16.81